Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals faces investor doubt as its stock plummets, lack of new milestones, and negative earnings raise concerns about future pain‑management prospects.

Tonix Pharmaceuticals (TNXP) gains 5% pre‑market as investors eye its CNS‑focused pipeline for fibromyalgia and PTSD, amid rising demand for precision therapies.

Tonix Pharmaceuticals is advancing CNS‑disorder therapies for fibromyalgia and PTSD, showing market resilience and investor confidence amid biotech volatility.

Tonix Pharmaceuticals reported Q1 2025 financial results, with a GAAP EPS of -$2.84 and revenue of $2.43 million, despite surpassing earnings expectations.